The Patent Finder

Onyvax Limited

Also on record
Records under this name other than patents Onyvax Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 7 of 7 · Back to Onyvax Limited

PatentTitleStatus Expires Confidence
US 8,097,244Human prostate cell lines in cancer treatment
Lapsed on the fee record
Ended Jan 17, 2024 · From the USPTO record
Lapsed on the fee recordEnded Jan 17, 2024From the USPTO record
US 7,438,922Human prostate cell lines in cancer treatment
Term ended
Term ended Oct 27, 2023 · From the USPTO record
Term endedTerm ended Oct 27, 2023From the USPTO record
US 8,545,835Human prostate cell lines in cancer treatment
Lapsed on the fee record
Ended Oct 1, 2021 · From the USPTO record
Lapsed on the fee recordEnded Oct 1, 2021From the USPTO record
US 6,699,483Cancer treatments
Term ended
Term ended Sep 7, 2021 · From the USPTO record
Term endedTerm ended Sep 7, 2021From the USPTO record
US 6,972,128Use of human prostrate cell lines in prostate cancer treatment
Term ended
Term ended Dec 9, 2019 · From the USPTO record
Term endedTerm ended Dec 9, 2019From the USPTO record
US 7,303,911Prostate cell lines
Lapsed on the fee record
Ended Dec 4, 2019 · From the USPTO record
Lapsed on the fee recordEnded Dec 4, 2019From the USPTO record
US 8,034,360Use of human prostate cell lines in cancer treatment
Lapsed on the fee record
Ended Oct 11, 2019 · From the USPTO record
Lapsed on the fee recordEnded Oct 11, 2019From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited